Literature DB >> 31597009

BETA-2 score is an early predictor of graft decline and loss of insulin independence after pancreatic islet allotransplantation.

Piotr J Bachul1, Justyna E Gołębiewska1,2, Lindsay Basto1, Karolina Gołąb1, Roi Anteby1,3, Ling-Jia Wang1, Martin Tibudan1, Celeste Thomas4, Wojciech Fendler5, Aaron Lucander1, Damian J Grybowski1, Alicja Dębska-Ślizień2, John Fung1, Piotr Witkowski1.   

Abstract

This study aimed to evaluate whether the BETA-2 score is a reliable early predictor of graft decline and loss of insulin independence after islet allotransplantation. Islet transplant procedures were stratified into 3 groups according to clinical outcome: long-term insulin independence without islet graft decline (group 1, N = 9), initial insulin independence with subsequent islet graft decline and loss of insulin independence (group 2, N = 13), and no insulin independence (group 3, N = 13). BETA-2 was calculated on day 75 and multiple times afterwards for up to 145 months posttransplantation. A BETA-2 score cut-off of 17.4 on day 75 posttransplantation was discerned between group 1 and groups 2 and 3 (area under the receiver operating characteristic 0.769, P = .005) with a sensitivity and negative predictive value of 100%. Additionally, BETA-2 ≥ 17.4 at any timepoint during follow-up reflected islet function required for long-term insulin independence. While BETA-2 did not decline below 17.4 for each of the 9 cases from group 1, the score decreased below 17.4 for all transplants from group 2 with subsequent loss of insulin independence. The reduction of BETA-2 below 17.4 predicted 9 (1.5-21) months in advance subsequent islet graft decline and loss of insulin independence (P = .03). This finding has important implications for posttransplant monitoring and patient care.
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; diabetes: type 1; islet transplantation; islets of Langerhans; quality of care/care delivery

Mesh:

Substances:

Year:  2019        PMID: 31597009     DOI: 10.1111/ajt.15645

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  3 in total

1.  Long-term Stability of β-Cell Graft Function After Total Pancreatectomy and Islet Autotransplantation.

Authors:  Piotr J Bachul; Karolina Golab; Lindsay Basto; Peter Borek; Laurencia Perea; Martin Tibudan; Jordan S Pyda; Angelica Perez-Gutierrez; John Fung; Jeffrey B Matthews; Piotr Witkowski
Journal:  Pancreas       Date:  2021-01-01       Impact factor: 3.243

2.  Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation.

Authors:  Piotr J Bachul; Karolina Golab; Lindsay Basto; Steven Zangan; Jordan S Pyda; Angelica Perez-Gutierrez; Peter Borek; Ling-Jia Wang; Martin Tibudan; Dong-Kha Tran; Roi Anteby; Gabriela S Generette; Jędrzej Chrzanowski; Wojciech Fendler; Laurencia Perea; Kumar Jayant; Aaron Lucander; Celeste Thomas; Louis Philipson; J Michael Millis; John Fung; Piotr Witkowski
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

3.  Estimation of Early Graft Function Using the BETA-2 Score Following Clinical Islet Transplantation.

Authors:  Anna Lam; Richard A Oram; Shareen Forbes; Tolu Olateju; Andrew J Malcolm; Sharleen Imes; A M James Shapiro; Peter A Senior
Journal:  Transpl Int       Date:  2022-07-06       Impact factor: 3.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.